All News

Found 96 articles

• MindMed Signs Partnership with Swiss Psychedelic Drug Discovery Startup MindShift Compounds AG, Expands Development Pipeline and IP Portfolio with Next-Gen Psychedelic and Empathogenic Compounds

  2/11/2021

  MindMed, a leading psychedelic medicine biotech company announced a new partnership with Swiss startup MindShift Compounds AG to develop and patent next-gen psychedelic compounds with psychedelic or empathogenic properties.

• MindMed Streamlines Leadership with Further Emphasis on Integrating Psychedelic Drug Development with Digital Medicines and Therapeutics

  2/2/2021

  J.R. Rahn to become sole CEO; Perry Dellelce to become Chair; Stephen Hurst retires as executive but remains on board; Stanley Glick retires as board member.

• MindMed Announces the Start of the First-Ever Clinical Trial Combining MDMA and LSD

  1/20/2021

  MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company, announced today the start of the first ever clinical trial measuring and evaluating MDMA and LSD used in combination in the human body.

• MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial Experience

  1/14/2021

   MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company today announced the addition of Robert Barrow , an accomplished pharmaceutical executive, as Chief Development Officer

• MindMed Expands Psychedelic Microdosing Division, Adds Groundbreaking Study Evaluating LSD Microdosing Through Next-Gen Digital Clinical Markers

  1/12/2021

  MindMed to Commence Groundbreaking LSD Microdosing Study Evaluating Benefits on Neuroplasticity, Sleep, Cognitive Enhancement Variables and Immune System Response on the Human Body

• MindMed Announces Successful Completion of Pre-IND Meeting with the FDA for Project Lucy

  12/14/2020

  MindMed (NEO: MMED, OTCQB: MMEDF, DE: MMQ), a leading psychedelic medicine biotech company today announced the successful completion of a pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) regarding the development of lysergic acid diethylamide (LSD) assisted therapy for an anxiety disorder.

• MindMed to Launch Albert, A Digital Medicine Division for Psychedelic Medicines

  11/24/2020

  MindMed, a leading psychedelic medicine biotech company, is establishing a digital medicine division known as Albert.

• MindMed Receives Approval of Protocol Design to Evaluate Microdoses of LSD For Adult ADHD In Phase 2a Clinical Trial from Swiss and Dutch Health Authorities

  11/16/2020

  Project Lucy Submits Pre-IND Briefing Package to the FDA; Agrees Q1 Interim Analysis of Swiss Phase 2a Trial of LSD Assisted Therapy for Anxiety Disorders

• MindMed Announces Q3 2020 Financial Results;

  11/13/2020

  MindMed (NEO: MMED) (OTCQB: MMEDF), a leading psychedelic medicine biotech company, has announced its third quarter financial results for the three and nine months ended September 30, 2020. 

• MindMed Announces the Completion of Phase 1 Study Measuring Dosing Effects of LSD

  11/2/2020

  Data to Support MindMed's Project Lucy in Preparing Phase 2b Trial for Anxiety Disorders

• MindMed Partners with NYU Langone Medical Center to Launch Groundbreaking Training Program for Psychedelic Therapies and Medicines

  10/5/2020

  MindMed To Provide Funding for Psychedelic Medicine Research Training Program at NYU Langone Health and NYU Grossman School of Medicine

• MindMed and Liechti Lab Announce R&D Collaboration On Psilocybin

  9/24/2020

  Mind Medicine (MindMed) Inc. (NEO: MMED)(OTC: MMEDF), the leading drug development company for psychedelic inspired medicines, announces that the company has been conducting R&D work on psilocybin in collaboration with the University Hospital Basel's Liechti Lab in a study to better understand and compare the altered states of consciousness induced by psilocybin and LSD.

• MindMed Confirms No Material Change

  9/23/2020

  Mind Medicine Inc., the leading neuro-pharmaceutical company for psychedelic inspired medicines announces, at the request of IIROC on behalf of the NEO Exchange, that MindMed's management is unaware of any material change in MindMed's operations that would account for the recent increase in market activity.

• Aziyo Biologics Announces New Appointments to Board of Directors

  9/21/2020

  Aziyo Biologics, Inc. (“Aziyo”), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, announced today that Maybelle Jordan, Vice President of Business Development of Biomerix Corporation, and Brigid Makes, former Senior Vice President and Chief Financial Officer of Miramar Labs, have joined its board of directors. Maybell

• MindMed Submits Application For NASDAQ Up-Listing, Appoints Canaccord Genuity As Financial Advisor

  9/21/2020

  Mind Medicine (MindMed) Inc. (NEO: MMED)(OTCQB: MMEDF)(DE: MMQ), the leading drug development company for psychedelic inspired medicines, is evaluating an expanded United States investor base through an up-listing on the NASDAQ Capital Market ("NASDAQ

• MindMed Announces First-Ever Clinical Trial Combining MDMA and LSD

  8/25/2020

  Mind Medicine Inc., the leading neuro-pharmaceutical company for psychedelic inspired medicines and the University Hospital Basel's Liechti Lab are now combining MDMA and LSD in a groundbreaking Phase 1 clinical trial.

• Mind Medicine (MindMed) Inc. Announces Q2 2020 Financial Results

  8/14/2020

  Mind Medicine (MindMed) Inc. (NEO: MMED OTCQB: MMEDF), the leading psychedelic pharmaceutical company, has announced its second quarter financial results for the three and six months ended June 30 , 2020. 

• MindMed Adds Psychedelic Assisted Therapy Expert Dr. Peter Gasser As Clinical Advisor For Project Lucy

  8/6/2020

  Mind Medicine Inc., the leading psychedelic pharmaceutical company, has engaged renowned psychedelic assisted therapy expert Dr. Peter Gasser as an advisor to its LSD experiential therapy program Project Lucy.

• MindMed Completes Dosing 18-MC Phase 1 Study

  7/28/2020

  Company, seeing early success, will advance preparations for Phase 2a clinical trial in opioid addiction

• MindMed Building Diverse Pipeline and Leadership Position in Psychedelic Inspired Medicines Industry

  6/26/2020

  MindMed Co-founders and Co-CEOs JR Rahn and Stephen Hurst to provide corporate update of activities and investor Q&A on July 2, 2020 at 1pm EDT